Moderna (NASDAQ:MRNA) just experienced the kind of stock move that biotech investors rarely see. The Moderna cancer vaccine result quickly became the center of that repricing. Shares surged 177% on August 19 after its personalized cancer therapy, intismeran autogene, succeeded in the Phase 3 INTerpath-001 melanoma trial. The treatment, developed with Merck and used alongside Keytruda, improved both recurrence-free survival and distant metastasis-free survival. It is also the first individualized mRNA cancer therapy to produce a positive Phase 3 result. By the close, Moderna had added roughly $44 billion in market value, according to the Financial Times.
But here is what makes the next stage more interesting. Investors have still not seen the detailed Phase 3 numbers. Overall-survival data also remain immature. Moderna and Merck plan to present the complete results at an upcoming medical meeting. That leaves four major questions that could determine whether this enormous valuation reset holds up.
Full Moderna Cancer Vaccine Phase 3 Numbers Could Reset Expectations
The headline result was clearly positive. INTerpath-001 met its primary endpoint of recurrence-free survival, or RFS. It also met the important secondary endpoint of distant metastasis-free survival, or DMFS. The study enrolled 1,137 patients with completely resected Stage IIB-IV melanoma. No new safety concerns were reported.
What we still do not know is how large the benefit actually was. Moderna and Merck have not disclosed the Phase 3 hazard ratios, absolute recurrence rates, survival curves, or detailed subgroup results. Those numbers matter because investors now have a very strong Phase 2 benchmark. The detailed Moderna cancer vaccine data will therefore matter far more than the headline alone.
At five years, the earlier KEYNOTE-942 study showed a 49% reduction in recurrence or death, with an RFS hazard ratio of 0.51. It also showed a 59% reduction in distant metastasis or death, with a DMFS hazard ratio of 0.41.
Management had already told investors that the Phase 3 trial included at least 18 months of follow-up for every patient. That was important because separation in Phase 2 became clearer over time.
So the next question is straightforward: does Phase 3 reproduce something close to those Phase 2 effect sizes? A statistically positive result matters. The magnitude of that result may matter even more for Moderna’s new valuation.
Overall Survival Remains The Bigger Clinical Test
Preventing melanoma from returning is clinically important. Preventing it from spreading is also important. But the question investors will eventually want answered is simpler: do patients receiving intismeran live longer?
That answer is not available yet. Moderna and Merck said the Phase 3 trial will continue evaluating overall survival, or OS. Analysts have therefore cautioned that the full clinical picture remains incomplete. The Moderna cancer vaccine story will remain incomplete until investors have a clearer view of survival.
The earlier Phase 2 study gives investors a reason to watch closely. At five years, intismeran plus Keytruda produced an exploratory OS hazard ratio of 0.47 versus Keytruda alone. However, the confidence interval stretched from 0.17 to 1.35. Only 14 deaths had occurred. That makes the result encouraging but far from definitive.
This distinction matters because RFS can mature well before OS in adjuvant cancer studies. Patients may also receive additional treatments after recurrence. That can make survival differences harder to establish.
For now, the Phase 3 success proves that the combination can meaningfully affect disease recurrence and metastatic spread. Mature OS data could provide a much stronger measure of long-term clinical value. If the survival result remains uncertain, investors will have to judge how much of that uncertainty is already reflected in the stock.
Regulatory Speed & Manufacturing Will Shape Commercial Timing
The clinical result is only one part of the story. The next step is turning it into an approved and commercially scalable product.
Moderna and Merck have said they plan to engage regulators regarding filing submissions. Reuters reported that the treatment could potentially reach the market in 2027. The regulatory path for the Moderna cancer vaccine will now depend on the strength and completeness of the final package.
That possibility did not appear from nowhere. Before the Phase 3 result, Moderna President Stephen Hoge told investors that a successful study could support consideration for priority review. He also said the company had established dedicated manufacturing capacity in Massachusetts. Moderna believed that facility could handle the initial commercial indication. Management said it could be ready the following year if development and regulatory steps went according to plan.
Still, intismeran is not a conventional off-the-shelf medicine. Each treatment is designed from the mutations found in an individual patient’s tumor. That requires sequencing, selecting neoantigens, manufacturing a customized mRNA product, and delivering it within a clinically useful timeline.
Regulators will therefore evaluate more than efficacy. Manufacturing consistency, turnaround times, safety, and quality controls will also matter.
A 2027 launch is possible, but the precise timing depends on the full dataset and regulatory discussions. The market has already moved ahead of those steps.
Other Tumor Types Must Validate The Platform Thesis
This may be the biggest question behind Moderna’s rally. The valuation increase appears too large to be about melanoma alone.
Reuters Breakingviews noted that Barclays had estimated roughly $3 billion of annual melanoma sales by 2035. Yet the market assigned tens of billions of dollars of additional value to Moderna after the announcement. Moderna and Merck also share the economics of intismeran, making broader oncology success increasingly important to the valuation argument.
That broader opportunity is already being tested. Management said intismeran was advancing through nine Phase 2 and Phase 3 studies across several cancers. These include non-small-cell lung cancer, renal-cell carcinoma, and multiple forms of bladder cancer. The renal-cell and muscle-invasive bladder studies were already fully enrolled at the July earnings call. The Moderna cancer vaccine platform therefore has several chances to prove whether melanoma is reproducible elsewhere.
Management has also explained why melanoma success could matter elsewhere. Checkpoint inhibitors already work in lung and bladder cancers, which supports the biological rationale for combining them with intismeran. Pancreatic and gastric cancers are less certain because checkpoint therapies have historically been less effective there.
That means melanoma has validated one important part of the platform. It has not yet proven that personalized mRNA cancer therapy will work broadly across tumor types. The next oncology readouts could therefore carry unusually large consequences for the current valuation.
Final Thoughts
Moderna’s Phase 3 result changes the company’s story in a meaningful way. A business that was heavily associated with COVID vaccines now has the first positive Phase 3 result for an individualized mRNA cancer therapy. That deserves attention. But the stock’s 177% one-day surge means investors are no longer paying only for proof of concept. They are also paying for what the platform might become.
That distinction shows up clearly in the valuation. As of August 19, Moderna traded at roughly 8.76x LTM enterprise value to revenue and 11.28x LTM price to sales. In June 2025, those multiples were only 0.95x and 3.36x, respectively. Meanwhile, LTM EV/EBITDA stood at negative 8.89x, EV/EBIT at negative 8.01x, and diluted P/E at negative 21.78x because the company remains loss-making.
That makes traditional earnings multiples less useful today. Sales-based valuations carry more weight.
The current valuation therefore reflects substantial expectations for future oncology revenue, regulatory execution, and success beyond melanoma. The upcoming Phase 3 details, mature survival data, regulatory progress, and results from other tumor types should provide better evidence for judging whether those expectations are justified.
Disclaimer: We do not hold any positions in the above stock(s). Read our full disclaimer here.
